Keratoconjunctivitis sicca (Sjögren’s syndrome eye component) - Symptoms, Causes, Treatment & Prevention

```html

Overview

Keratoconjunctivitis sicca (KCS), commonly known as dry eye disease, is the ocular manifestation of Sjögren’s syndrome. In this autoimmune disorder, the body’s immune system mistakenly attacks the moisture‑producing glands, leading to persistent dryness of the eyes and mouth. When the eye component predominates, patients experience inflammation of the cornea (keratitis) and conjunctiva (conjunctivitis) due to inadequate tear production.

• Who it affects: Primarily middle‑aged women (≈ 9 women : 1 man), though men and children can be affected.
• Prevalence: Sjögren’s syndrome affects about 0.1–0.6 % of the general population; up to 70 % of those individuals develop KCS at some point (CDC, 2023).

Symptoms

Symptoms may be mild at first and progress over months or years. Common ocular complaints include:

• Foreign‑body sensation – feeling like sand or grit in the eye.
• Burning, stinging, or itching – often worse in dry or windy environments.
• Redness – due to chronic inflammation of the conjunctiva.
• Excessive tearing (reflex tearing) – paradoxical watery eyes that don’t lubricate the surface.
• Blurred vision – especially after reading, using a computer, or watching TV.
• Light sensitivity (photophobia) – discomfort in bright light.
• Difficulty wearing contact lenses – lenses become uncomfortable quickly.
• Stringy mucus or discharge – from the meibomian glands.
• Recurrent eye infections – due to impaired tear film defense.

Systemic Sjögren’s symptoms (dry mouth, joint pain, fatigue) often coexist, but the eye component can be the first sign of disease.

Causes and Risk Factors

KCS in Sjögren’s syndrome is not caused by a single factor; it results from a complex interaction of genetics, immune dysregulation, and environmental triggers.

Underlying Mechanism

• Autoimmune attack: Auto‑antibodies (anti‑SSA/Ro, anti‑SSB/La) target the lacrimal glands, reducing aqueous tear production.
• Inflammation of meibomian glands: Leads to a deficient oily layer, causing rapid tear evaporation.
• Neuropathic changes: Damage to sensory nerves diminishes the blink reflex and tear‑film stability.

Risk Factors

• Female sex (peak incidence 40‑60 years).
• Family history of autoimmune disease.
• Other connective‑tissue disorders (e.g., rheumatoid arthritis, systemic lupus erythematosus).
• Prior ocular surgery (LASIK, cataract) that may exacerbate tear film instability.
• Medications that decrease tear production (antihistamines, antidepressants, isotretinoin).
• Environmental exposures – dry climates, wind, air‑conditioned or heated indoor air.

Diagnosis

Diagnosing KCS involves a combination of symptom assessment, clinical examination, and objective testing.

Step‑by‑step diagnostic pathway

1. History taking: Physician documents ocular symptoms, systemic Sjögren’s features, medication use, and occupational exposures.
2. Schirmer test: Strips of filter paper placed under the lower eyelid for 5 minutes; ≤5 mm wetting suggests severe aqueous deficiency.
3. Tear Break‑Up Time (TBUT): Fluorescein dye is applied and the interval until the first dry spot appears is measured; <10 seconds is abnormal.
4. Ocular surface staining: Lissamine green or rose bengal highlights damaged epithelial cells; a higher staining grade correlates with disease severity.
5. Meibomian gland evaluation: Expressibility and quality of the oily secretion are assessed.
6. Serologic tests (if Sjögren’s is suspected): ANA, anti‑SSA/Ro, anti‑SSB/La, rheumatoid factor.
7. Imaging: In refractory cases, ultrasound or MRI of lacrimal glands can rule out obstructive causes.

International consensus (DEWS II, 2017) recommends using at least two objective tests plus symptom questionnaires (e.g., OSDI – Ocular Surface Disease Index) for a reliable diagnosis.

Treatment Options

Treatment is individualized, aiming to restore a stable tear film, control inflammation, and protect the ocular surface.

1. Artificial Tears & Lubricants

• Preservative‑free drops: 1‑2 × per hour initially, then tapered based on relief.
• Gel or ointment preparations: Used at night for prolonged coverage.
• Examples: Refresh Optive®, Systane Ultra®, or preservative‑free nano‑emulsion drops (e.g., Lifitegrast has both lubricating and anti‑inflammatory properties).

2. Anti‑Inflammatory Medications

• Corticosteroid eye drops: Short‑term (e.g., prednisolone 0.5 %) for acute inflammation; limited to ≤2 weeks to avoid glaucoma or cataract.
• Cycloplegic agents (e.g., cyclosporine 0.05 % – Restasis®): Improves tear production by inhibiting T‑cell activation; may take 4‑6 weeks for effect.
• Lifitegrast 5 % (Xiidra®): An LFA‑1 antagonist that reduces ocular surface inflammation; approved for dry eye disease.
• Topical corticosteroid‑sparing agents: Tetracycline derivatives (doxycycline 100 mg PO daily) help modify meibomian gland secretions.

3. Punctal Occlusion

Silicone or collagen plugs placed in the lacrimal puncta block tear drainage, retaining the patient’s natural tears. Long‑term success rates range from 60‑80 % (Cleveland Clinic, 2022).

4. Autologous Serum Eye Drops

Prepared from the patient’s own blood, these drops contain growth factors and vitamins that promote epithelial healing. Typically 20 % concentration, used 4–6 × daily for severe refractory cases.

5. Meibomian Gland Therapies

• Lipid‑based artificial tears (e.g., Systane Balance®).
• Thermal pulsation (LipiFlow®) or IPL (intense pulsed light) to melt obstructed meibum.
• Manual expression performed by an ophthalmologist.

6. Protective Eyewear & Environmental Modifications

• Wrap‑around glasses to reduce wind exposure.
• Humidifiers maintaining indoor humidity at 40‑55 %.
• Screen‑time breaks (20‑20‑20 rule: every 20 min, look at something 20 ft away for 20 seconds).

7. Systemic Therapies (for systemic Sjögren’s)

When ocular disease reflects active systemic autoimmunity, rheumatologists may prescribe hydroxychloroquine, rituximab, or other disease‑modifying agents. Control of systemic disease often improves ocular symptoms.

Living with Keratoconjunctivitis Sicca (Sjögren’s Syndrome Eye Component)

Long‑term management focuses on symptom control, protecting the ocular surface, and monitoring for complications.

Daily Management Tips

1. Follow a strict drop schedule: Keep a log; use preservative‑free options and avoid sharing bottles.
2. Stay hydrated: Aim for 2–3 L of water daily; dehydration worsens tear osmolarity.
3. Maintain a balanced diet rich in omega‑3 fatty acids: Fatty fish, flaxseed, or fish‑oil supplements (1 g/day) have modest benefit (NIH, 2021).
4. Use a humidifier in bedroom and office.
5. Protect eyes from irritants: Smoke, strong perfumes, and air‑conditioned drafts.
6. Warm compresses & lid hygiene: 5‑minute warm compress followed by gentle lid massage twice daily to improve meibomian gland function.
7. Schedule regular eye exams: At least every 6 months, or sooner if symptoms change.
8. Monitor systemic disease: Coordinate care with a rheumatologist; systemic flares often precede ocular worsening.

Activity Modifications

• When reading or using screens, increase ambient humidity and use artificial tear “pre‑loading.”
• Wear sunglasses outdoors to reduce UV‑induced ocular surface damage.
• Avoid swimming pools with chlorine; use lubricating eye shields if exposure is unavoidable.

Prevention

While Sjögren’s syndrome cannot be prevented, steps can reduce the risk of developing clinically significant dry eye or aggravating existing disease:

• Control systemic autoimmune disease promptly.
• Limit use of medications known to reduce tear production; discuss alternatives with your physician.
• Adopt a smoke‑free lifestyle.
• Maintain optimal indoor humidity and avoid prolonged exposure to air‑conditioning or heating vents.
• Use protective eyewear when working in dusty or windy environments.

Complications

If left untreated, chronic keratoconjunctivitis sicca can lead to serious ocular sequelae:

• Corneal epithelial breakdown – recurrent erosions, ulceration, and potential scarring.
• Superinfection: Bacterial, fungal, or viral keratitis due to compromised surface defense.
• Filamentary keratitis: Mucus‑laden strands adhering to the cornea, causing pain.
• Conjunctival scarring and goblet‑cell loss: Further reduces tear film stability.
• Vision‑threatening complications: Persistent ulceration may lead to perforation or need for corneal transplantation.
• Impact on quality of life: Chronic discomfort, reduced productivity, and psychosocial stress.

When to Seek Emergency Care

---

Sources: Mayo Clinic, CDC (2023), National Institutes of Health, World Health Organization, Cleveland Clinic, DEWS II Report (2017), peer‑reviewed journals (Ocular Surface, 2022‑2024).

```